Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A Systematic Review

Objectives. To evaluate the ability of the c-reactive protein-to-albumin ratio (CAR) in predicting outcomes in patients undergoing pancreatic cancer resection. Methods. A systematic search of electronic information sources and bibliographic reference lists was conducted. Survival outcomes and perioperative morbidity were the evaluated outcome parameters. Results. Eight studies reporting a total of 1056 patients undergoing pancreatic cancer resection were identified. The median cut-off value for CAR was 0.05 (range 0.0003–0.54). Using multivariate analysis, all studies demonstrated that a higher CAR value was an independent and significant predictor of poor overall survival in patients undergoing pancreatic cancer resection. The estimated hazard ratio (HR) ranged from 1.4 to 3.6. Although there was a positive correlation between the reported cut-off values for CAR and HRs for overall survival, it was weak and non-significant (r = 0.36, n = 6, p = 0.480). There was significant between-study heterogeneity. Conclusions. Preoperative CAR value seems to be an important prognostic score in predicting survival outcomes in patients undergoing pancreatic cancer resection. However, the current evidence does not allow the determination of an optimal cut-off value for CAR, considering the heterogeneous reporting of cut-off values by the available studies and the lack of knowledge of their sensitivity and specificity. Future research is required.

[1]  T. Masaki,et al.  Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer , 2020, BMC Gastroenterology.

[2]  G. Patijn,et al.  The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection , 2020, European Journal of Medical Research.

[3]  Yu Fan,et al.  Pretreatment C-reactive protein/albumin ratio for predicting overall survival in pancreatic cancer , 2020, Medicine.

[4]  Z. Liang,et al.  C-reactive protein/albumin ratio is a prognostic indicator in Asians with pancreatic cancers , 2019, Medicine.

[5]  P. Kornprat,et al.  The Predictive Value of the CRP–to–Albumin Ratio for Patients With Pancreatic Cancer After Curative Resection: A Retrospective Single Center Study , 2019, In Vivo.

[6]  N. Yamanaka,et al.  Preoperative C‐reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma , 2019, Asia-Pacific journal of clinical oncology.

[7]  E. Steyerberg,et al.  Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer , 2019, The British journal of surgery.

[8]  J. Emond,et al.  Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma , 2018, Journal of hepatocellular carcinoma.

[9]  M. Preusser,et al.  The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction , 2018, Oncotarget.

[10]  Wei-min Li,et al.  Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis , 2017, PloS one.

[11]  K. Endo,et al.  C-Reactive Protein/Albumin Ratio and Prognostic Nutritional Index Are Strong Prognostic Indicators of Survival in Resected Pancreatic Ductal Adenocarcinoma , 2017, Journal of pancreatic cancer.

[12]  Lu Shi,et al.  Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. , 2017, Cancer Treatment Reviews.

[13]  P. Xue,et al.  Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients , 2017, Scientific Reports.

[14]  Z. Nie,et al.  A nomogram based on serum bilirubin and albumin levels predicts survival in gastric cancer patients , 2017, Oncotarget.

[15]  F. Habibzadeh,et al.  On determining the most appropriate test cut-off value: the case of tests with continuous results , 2016, Biochemia medica.

[16]  H. Sorbye,et al.  Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer , 2016, Oncotarget.

[17]  Jae Min Lee,et al.  Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. , 2016, World journal of gastrointestinal oncology.

[18]  Q. Zuo,et al.  The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer , 2016, Tumor Biology.

[19]  T. Misawa,et al.  The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection , 2016, World Journal of Surgery.

[20]  S. Barni,et al.  The Modified Glasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature. , 2015, Reviews on recent clinical trials.

[21]  J. Ahmad,et al.  Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[22]  K. Hanazaki,et al.  S-1 vs. Gemcitabine as an Adjuvant Therapy after Surgical Resection for Ductal Adenocarcinoma of the Pancreas , 2014, World Journal of Surgery.

[23]  D. Morris,et al.  A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. , 2014, Surgical oncology.

[24]  D. McMillan The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. , 2013, Cancer treatment reviews.

[25]  P. Kornprat,et al.  Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer , 2013, British Journal of Cancer.

[26]  D. Gupta,et al.  Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature , 2010, Nutrition journal.

[27]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[28]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[29]  D. Manas,et al.  Liver resection for colorectal liver metastasis. , 2007, Surgical oncology.

[30]  C. McArdle,et al.  Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer , 2007, International Journal of Colorectal Disease.

[31]  Michael A. Choti,et al.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.

[32]  M. Karin Nuclear factor-κB in cancer development and progression , 2006, Nature.

[33]  R. Kurzrock,et al.  Cytokines in pancreatic carcinoma , 2004, Cancer.

[34]  Murray F. Brennan,et al.  Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the Pancreas , 2004, Annals of surgery.

[35]  C. McArdle,et al.  Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer , 2004, British Journal of Cancer.

[36]  F. López‐Soriano,et al.  Cytokines in the pathogenesis of cancer cachexia , 2003, Current opinion in clinical nutrition and metabolic care.

[37]  M. Morimoto,et al.  Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study , 2019, In Vivo.

[38]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[39]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[40]  J. Ross,et al.  Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. , 1999, Nutrition and cancer.

[41]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.